# A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

> **NCT05002569** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 1093 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Nivolumab + Relatlimab Fixed Dose Combination

## Key facts

- **NCT ID:** NCT05002569
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-19
- **Primary completion:** 2024-12-16
- **Final completion:** 2025-04-02
- **Target enrollment:** 1093 (ACTUAL)
- **Why stopped:** Inability to meet protocol objectives
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002569, "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05002569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*